MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

類似資料

• E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy
  著者:: Claudiani, Simone, 等
  出版事項: (2017)
• Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
  著者:: Claudiani, Simone, 等
  出版事項: (2020)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  著者:: Nteliopoulos, Georgios, 等
  出版事項: (2019)
• Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
  著者:: Milojkovic, Dragana, 等
  出版事項: (2012)
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
  著者:: Ibrahim, Amr R., 等
  出版事項: (2010)